Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | CD44 | P16070 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11537869 | 0.80 | KDM4E (0.44) | KMT2AADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL18322409 | 0.77 | PNMT (0.43) | KMT2APNMTCD44MAOBHTR2C | |
| Hydrochloric Acid SCHEMBL18706568 | 0.76 | PNMT (0.42) | KMT2APNMTCD44MAOBHTR2C | |
| SCHEMBL23966212 | 0.75 | BRD4 (0.52) | KMT2AADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL23981768 | 0.71 | KMT2A (0.41) | KMT2AHTR2CALOX12KDM4ECYP2C19 | |
| SCHEMBL20351801 | 0.71 | PNMT (0.38) | KMT2APNMTCD44MAOBHTR2C | |
| SCHEMBL18611005 | 0.69 | BRD4 (0.43) | KMT2AADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL1011335 | 0.69 | ALDH1A1 (0.52) | KMT2APNMTCD44MAOBALOX12 | |
| SCHEMBL29789782 | 0.69 | ALDH1A1 (0.52) | KMT2APNMTCD44MAOBALOX12 | |
| SCHEMBL18322610 | 0.68 | OXTR (0.43) | KMT2APNMTCD44MAOBADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | KMT2A 4577/4885PNMT 3435/4885CD44 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.